Top six pharmaceutical stocks to watch in September

Follow us on Google News:
 Top six pharmaceutical stocks to watch in September
Image source: Billion Photos,Shutterstock

Highlights

  • The Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM) stock surged by 16.17 percent on Wednesday after announcing a collaboration with Texas University.
  • Teva Pharmaceutical Industries Limited (NYSE: TEVA) reported revenue of US$3.9 billion in Q2, 2021.
  • Nuvation Bio Inc (NYSE: NUVB) reported a net loss of US$19.33 million in Q2, 2021.

Pharmaceuticals companies manufacture drugs for various diseases. The healthcare sector has received a significant fiscal boost as part of efforts to contain the spread of coronavirus. The Biden administration has allocated billions of dollars to revamp the health infrastructure to meet the challenges. Therefore, the sector has been receiving increased attention from investors. On Wednesday, the Dow Jones US Pharmaceuticals Index, which comprises the top American healthcare companies, was down 0.63% at 11.48 am ET.

Here we explore six pharmaceutical stocks that may benefit from Biden’s healthcare push.

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM)

The Texas-based biopharmaceutical company develops cancer drugs. Its stocks traded at US$3.52 percent in the premarket on September 1, up 16.17 percent from the previous close. On Wednesday, the company announced a partnership with the Cancer Centre of Texas University. Both sides would collaborate on intellectual property rights for cancer research. 

In Q2 of 2021, the company’s total revenue was US$0.70 million, and the net loss was US$2.20 million. In Q2 of 2020, its losses were US$43.19 million.

Bellicum’s market cap is US$30 million. The BLCM stock fell by 14.16 percent YTD. Its 52-week highest and lowest stock prices were US$8.19 and US$2.57, respectively, and the forward P/E one year is -0.54.

Also read: Four pharma stocks to watch this fall

Teva Pharmaceutical Industries Limited (NYSE: TEVA)

The Israeli-based pharm company develops specialty medicines.

The company’s total revenue in Q2, 2021, was US$3.9 billion against US$3.8 billion in Q2 last year. The gross profit for the period was US$1.9 billion against US$1.7 billion in Q2, 2020. In addition, the company’s net income was US$207 million compared to US$140 million in Q2, 2020. 

Teva has a market cap of US$10.3 billion. The stock traded at US$9.415 at 10.45 am ET on Sep 1, down 0.05 percent. The stock fell 2.33 percent YTD. Its 52-week highest and lowest stock prices were US$13.30 and US$8.24, respectively, the forward P/E one year is 3.75, and the EPS is US$-3.57.

Source: Pixabay.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO)

The Taro company is also based in Israel and markets over 200 medicines in more than 25 countries. It owns medicine brands like Topicort.

The company’s revenue in Q2, 2021, was US$147.1 million against US$117.6 million in Q2, 2020. The gross profit for the period was US$77.7 million compared to US$64.9 million in Q2, 2021. The company reported losses of US$18.8 million in the quarter compared to US$434.9 million in Q2, 2020.

The stock traded at US$67.79 at 10.53 am ET on September 1, down 0.04 percent from the previous close. The stock fell by 8.32 percent YTD.

Taro has a market cap of US$2.5 billion, a P/E ratio of 88.57, and a forward P/E one year of 16.11. Its EPS is US$0.76. Taro’s 52-week highest and lowest stock prices were US$80 and US$53.95, respectively.

Nuvation Bio Inc (NYSE: NUVB)

It is a California-based biopharmaceutical company and develops therapies for various types of cancer.

The company reported a net loss of US$19.33 million in Q2, 2021. Its market cap is US$2 billion, the forward P/E one year is -20.51, and the 52-week highest and lowest stock prices were US$15.23 and US$7.66, respectively.

The NUVB stock traded at US$9.35 at 11.14 am ET on September 1, up 1.30 percent from the previous close. The stock fell 20.09 percent YTD.

 

Source: Pixabay.

Arcus Biosciences, Inc (NYSE: RCUS)

The clinical-stage biotechnology company develops cancer immunotherapy. Its stock traded at US$30.295 at 11.24 am ET on September 1, up by 4.05 percent over the August 31 closing price. Its stock price went up by 15.79 percent YTD.

The company had total revenue of US$9.46 million in Q2, 2021, and US$1.75 million in Q2, 2020. The company incurred losses of US$75.97 million in Q2, 2021, and US$45.07 million in Q2, 2020.

Its market capitalization is US$2.1 billion. The forward P/E one year is -6.78 and the EPS is US$-2.96. The highest and lowest stock prices of the RCUS for the past 52 weeks were US$42.36 and US$16.69.

Horizon Therapeutics Public Limited (Nasdaq: HZNP)

The Horizon biotechnology company is based in California and develops drugs for inflammatory diseases.

In Q2 of 2021, the company’s total revenue was US$832.5 million compared to US$462.8 million in Q2, 2020. Its gross profit was US$631.6 million against US$341.3 million in Q2, 2020. In addition, the company’s net income was US$158.1 million compared to a loss of US$80 million in Q2, 2020.

Also read: Check out these fastest-growing small-cap healthcare stocks

Horizon’s market cap is US$24.8 billion, the P/E ratio is 48.86, and the forward P/E one year is 24.85. Its EPS is US$2.25. Horizon’s 52-week highest and lowest stock prices were US$111.33 and US$66.41, respectively.

The stock traded at US$109.87 at 11.42 am ET on September 1, up 1.75 percent from the previous close. The stock surged 50.48 percent YTD.


Bottomline

The pharmaceutical companies have been seen robust revenue growth in recent quarters. In addition, the coronavirus outbreak has been a blessing in disguise for some companies. Analysts expect robust growth of the sector in the coming months.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Featured Articles